Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Genetics
Volume 2014 (2014), Article ID 413743, 4 pages
http://dx.doi.org/10.1155/2014/413743
Case Report

Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes

1Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA 22601, USA
2PinnacleHealth, Harrisburg, PA 17109, USA

Received 31 October 2013; Accepted 19 November 2013; Published 22 January 2014

Academic Editors: F.-C. Hsu, B. Melegh, L. Parnell, and P. Saccucci

Copyright © 2014 Mark Johnson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Eriksson and M. Wadelius, “Prediction of warfarin dose: why, when and how?” Pharmacogenomics, vol. 13, no. 4, pp. 429–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. F. Carlquist and J. L. Anderson, “Using pharmacogenetics in real time to guide warfarin initiation: a clinician update,” Circulation, vol. 124, no. 23, pp. 2554–2559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. D. S. Budnitz, M. C. Lovegrove, N. Shehab, and C. L. Richards, “Emergency hospitalizations for adverse drug events in older Americans,” The New England Journal of Medicine, vol. 365, no. 21, pp. 2002–2012, 2011. View at Google Scholar · View at Scopus
  4. K. Takanashi, H. Tainaka, K. Kobayashi, T. Yasumori, M. Hosakawa, and K. Chiba, “CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates,” Pharmacogenetics, vol. 10, no. 2, pp. 95–104, 2000. View at Google Scholar · View at Scopus
  5. T. Li, C.-Y. Chang, D.-Y. Jin, P.-J. Lin, A. Khvorova, and D. W. Stafford, “Identification of the gene for vitamin K epoxide reductase,” Nature, vol. 427, no. 6974, pp. 541–544, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Rieder, A. P. Reiner, B. F. Gage et al., “Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose,” The New England Journal of Medicine, vol. 352, no. 22, pp. 2285–2293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. H.-Y. Yuan, J.-J. Chen, M. T. M. Lee et al., “A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity,” Human Molecular Genetics, vol. 14, no. 13, pp. 1745–1751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Fukuda, T. Tanabe, M. Ohno et al., “Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes,” Clinical Pharmacology and Therapeutics, vol. 80, no. 5, pp. 553–554, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. Coumadin, Package Insert, Bristol-Myers Squibb, Princeton, NJ, USA, 2011.
  10. T. E. Klein, R. B. Altman, N. Eriksson et al., “Estimation of the warfarin dose with clinical and pharmacogenetic data,” The New England Journal of Medicine, vol. 360, no. 8, pp. 753–764, 2009. View at Publisher · View at Google Scholar
  11. G. R. Grice, P. E. Milligan, C. Eby, and B. F. Gage, “Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive,” Journal of Thrombosis and Haemostasis, vol. 6, no. 1, pp. 207–209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Goto, M. Miura, A. Murata et al., “Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria,” Clinica Chimica Acta, vol. 411, no. 17-18, pp. 1375–1377, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Gao, L. He, J. Luo et al., “Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A,” Chinese Medical Journal, vol. 124, no. 17, pp. 2767–2770, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. B. F. Gage, C. Eby, J. A. Johnson et al., “Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin,” Clinical Pharmacology and Therapeutics, vol. 84, no. 3, pp. 326–331, 2008. View at Publisher · View at Google Scholar · View at Scopus